{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T01:04:06Z","timestamp":1789866246641,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.urolonc.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:01:16Z","timestamp":1789862476000},"page":"897-910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The AURKA\u2013PTTG1 signaling axis induces enzalutamide resistance in prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Guangye","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10305","key":"10.1016\/j.urolonc.2026.08.010_bib0001","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.010_bib0002","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MOU.0000000000000984","article-title":"Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management","volume":"32","author":"Jazayeri","year":"2022","journal-title":"Curr Opin Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.010_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020327","article-title":"Resistance to antiandrogens in prostate cancer: is it inevitable, intrinsic or induced?","volume":"13","author":"Maitland","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.urolonc.2026.08.010_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215447","article-title":"The neglected liaison: targeting cancer cell metabolic reprogramming modifies the composition of non-malignant populations of the tumor microenvironment","volume":"13","author":"Iorio","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.010_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032606","article-title":"Modulating glycolysis to improve cancer therapy","volume":"24","author":"Chelakkot","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.010_bib0006","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neo.2020.12.009","article-title":"Glycolysis-induced drug resistance in tumors-A response to danger signals?","volume":"23","author":"Marcucci","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.urolonc.2026.08.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000002058.12","article-title":"PD44-12\u2003enzalutamide enhances glycolysis in castration-resistant prostate cancer","volume":"206","author":"Liu","year":"2021","journal-title":"J Urol"},{"issue":"1455","key":"10.1016\/j.urolonc.2026.08.010_bib0008","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1098\/rstb.2004.1615","article-title":"Basic mechanism of eukaryotic chromosome segregation","volume":"360","author":"Yanagida","year":"2005","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.010_bib0009","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1083\/jcb.200506119","article-title":"Separase: a universal trigger for sister chromatid disjunction but not chromosome cycle progression","volume":"172","author":"Wirth","year":"2006","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.010_bib0010","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1186\/s12885-024-13060-5","article-title":"Multi-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance","volume":"24","author":"Wei","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2026.08.010_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e13201","article-title":"Elevated PTTG1 predicts poor prognosis in kidney renal clear cell carcinoma and correlates with immunity","volume":"9","author":"Zhang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.urolonc.2026.08.010_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.843579","article-title":"A comprehensive pan-cancer analysis for pituitary tumor-transforming gene 1","volume":"13","author":"Gong","year":"2022","journal-title":"Front Genet"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.010_bib0013","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s12325-021-01729-3","article-title":"CDC20 and PTTG1 are important biomarkers and potential therapeutic targets for metastatic prostate cancer","volume":"38","author":"Dai","year":"2021","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.urolonc.2026.08.010_bib0014","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/cas.13493","article-title":"Interleukin-6\/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression","volume":"109","author":"Huang","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2026.08.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108633","article-title":"Aurora kinases, emerging critical targets for cancer treatment and related new therapeutic strategies","volume":"163","author":"Chung","year":"2025","journal-title":"Bioorg Chem"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.010_bib0016","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13058-024-01882-x","article-title":"Elevated expression of Aurora-A\/AURKA in breast cancer associates with younger age and aggressive features","volume":"26","author":"Ingebriktsen","year":"2024","journal-title":"Breast Cancer Res"},{"issue":"47","key":"10.1016\/j.urolonc.2026.08.010_bib0017","article-title":"FBXO44 Regulates FOXP1 degradation through AURKA-dependent phosphorylation to promote colorectal cancer progression","volume":"12","author":"Nie","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.urolonc.2026.08.010_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/carcin\/bgaf054","article-title":"The oncogenic role of AURKA in gastric cancer: mechanisms, pathways, and clinical relevance","author":"Lv","year":"2025","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.010_bib0019","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41420-023-01341-0","article-title":"HMMR promotes prostate cancer proliferation and metastasis via AURKA\/mTORC2\/E2F1 positive feedback loop","volume":"9","author":"Guo","year":"2023","journal-title":"Cell Death Discov"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.010_bib0020","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41419-023-05894-x","article-title":"Neurokinin-1 receptor drives PKCa-AURKA\/N-myc signaling to facilitate the neuroendocrine progression of prostate cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2282184","article-title":"Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA","volume":"56","author":"Chen","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.urolonc.2026.08.010_bib0022","article-title":"ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer","volume":"13","author":"Cen","year":"2025","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.08.010_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkab038","article-title":"Integrating quantitative proteomics with accurate genome profiling of transcription factors by greenCUT&RUN","volume":"49","author":"Nizamuddin","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.urolonc.2026.08.010_bib0024","article-title":"Identification of protein subcellular localization with network and functional embeddings","volume":"11","author":"Pan","year":"2020","journal-title":"Front Genet"},{"issue":"32","key":"10.1016\/j.urolonc.2026.08.010_bib0025","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/s41388-023-02767-7","article-title":"Phosphorylated PTTG1 switches its subcellular distribution and promotes beta-catenin stabilization and subsequent transcription activity","volume":"42","author":"Zhang","year":"2023","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.010_bib0026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00383-025-06246-w","article-title":"Inhibition of PTTG1 suppresses proliferation and promotes differentiation of neuroblastoma cells by inducing autophagy","volume":"42","author":"Yuan","year":"2025","journal-title":"Pediatr Surg Int"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.010_bib0027","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/1878-0261.13779","article-title":"The PTTG1\/VASP axis promotes oral squamous cell carcinoma metastasis by modulating focal adhesion and actin filaments","volume":"19","author":"Park","year":"2025","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.08.010_bib0028","doi-asserted-by":"crossref","first-page":"70 e11","DOI":"10.1016\/j.urolonc.2025.09.005","article-title":"PTTG1-mediated reprogramming of asparagine metabolism enhances DNA damage repair and leads to compromised antitumor immunity in prostate cancer","volume":"44","author":"Ma","year":"2026","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.08.010_bib0029","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/0008-5472.CAN-21-2988","article-title":"EIF4A3-Induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2\/c-Myc\/LDHA signaling","volume":"82","author":"Jiang","year":"2022","journal-title":"Cancer Res"},{"issue":"Pt 2","key":"10.1016\/j.urolonc.2026.08.010_bib0030","article-title":"Glycolysis related lncRNA SNHG3 \/miR-139-5p \/ PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance","volume":"260","author":"Yao","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.08.010_bib0031","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","article-title":"The cellular geography of aurora kinases","volume":"4","author":"Carmena","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.urolonc.2026.08.010_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103137","article-title":"Meningioma achieves malignancy and erastin-induced ferroptosis resistance through FOXM1-AURKA-NRF2 axis","volume":"72","author":"Ye","year":"2024","journal-title":"Redox Biol"},{"key":"10.1016\/j.urolonc.2026.08.010_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1106175","article-title":"CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine","volume":"13","author":"Chen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.urolonc.2026.08.010_bib0034","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jamaoncol.2022.7949","article-title":"Evaluation of Alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial","volume":"9","author":"Haddad","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:32:44Z","timestamp":1789864364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1078143926007052"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The AURKA\u2013PTTG1 signaling axis induces enzalutamide resistance in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}